依普利酮主要治疗什么病症？

It is a new type of selective aldosterone receptor blocker. Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that eplerenone can also be used for congestive heart failure after acute myocardial infarction. Eplerenone can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.

Subgroup analysis of the EPHESUS study also showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone in reducing systolic blood pressure (14.5 mmHg for eplerenone; 12.7 mmHg for enalapril: P=0.199) and diastolic blood pressure (11.2 mmHg for eplerenone; 11.3 mm for enalapril). Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). Dropout due to adverse events (7.9% for eplerenone and 9.3% for enalapril at 6 months) and treatment failure rates were also equal (23.3% for eplerenone and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone group was more significant (-61.5% vs -25.7%; P=0.01). Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%), and clinical trials have proven that it can also be used for congestive heart failure after acute myocardial infarction.